- Home
- BANC vs RCUS Comparison
BANC vs RCUS Comparison
Compare BANC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANC | RCUS |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BANC | RCUS |
|---|---|---|
| Price | $19.99 | $21.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $21.39 | ★ $28.89 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 01-21-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $1,019,965,000.00 | $240,000,000.00 |
| Revenue This Year | $4.33 | N/A |
| Revenue Next Year | $13.97 | N/A |
| P/E Ratio | $19.42 | ★ N/A |
| Revenue Growth | ★ 147.22 | N/A |
| 52 Week Low | $11.52 | $6.50 |
| 52 Week High | $21.61 | $26.40 |
Technical Indicators
Market Signals| Indicator | BANC | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 43.08 |
| Support Level | $19.67 | $21.82 |
| Resistance Level | $20.41 | $23.50 |
| Average True Range (ATR) | 0.58 | 1.27 |
| MACD | -0.11 | -0.12 |
| Stochastic Oscillator | 15.46 | 10.63 |
Price Performance
Historical ComparisonAbout BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.